Announced
that the Food and Drug Administration on Monday trading license a new
drug was described as a "last option" for the treatment of AIDS patients
who have failed all other attempts at treatment.
The news report said that the point of force major new drug, which make it more useful than previous drugs, is in its ability to delay the spread of the disease. The ability of HIV to spread is responsible for causing the most serious symptoms and side effects of the failure of the most vital body functions.
The significance of the new drug which is dubbed "Stlesntre" (Selzentry) is that the only drug in the world markets, which he can close the one most important entry points used by HIV to destroy the white blood cells responsible for immunity of the body, known as the "agent receiver CCR5".
Pfizer Inc. said U.S. manufacturer of the drug that the drug will be available in the market from next month, and confirmed that its price will be equal to the price of similar drugs.
He said experts are neutral, that feature the new drug is its ability to respond to the disease in advanced stages make it the first of a new generation of treatment, as research has shown that people with defects in the work of CCR5 are better protected against AIDS, and its spread within their bodies in case of infection is very slow .
But experts have suggested that the only obstacle to the production of a drug intended to treat "factor reception CCR5," was the high proportion of dangerous side effects, and the possibility of exposure to significant damage to the heart or liver, as well as increase the risk of infections and the spread of cancer.
However, the Food and Drug Administration has not gone unnoticed by those caveats, is viewed as consent to "Stlesntre" comes in the context of the granting of "new option" for patients with difficult cases, calling the manufacturer to carry out more developmental research.
And Drug Affairs Officer suspended in the administration, Dr. Debra Brinkerant "draw benefit from the drug outweigh harms, and this does not mean that the risks do not exist ... the drug is designated for the process of his body has become resistant to various types of AIDS medicines, which is not for people with recently."
The researchers say that HIV known as HIV, which currently comes in fourth place in the list of diseases, the most deadly after heart disease, stroke and respiratory diseases - is about to occupy the third place, where he is the disease on approximately 2.8 million people annually.
Researchers predict that the number of deaths with the disease over the next twenty-five to about 120 million people.
The news report said that the point of force major new drug, which make it more useful than previous drugs, is in its ability to delay the spread of the disease. The ability of HIV to spread is responsible for causing the most serious symptoms and side effects of the failure of the most vital body functions.
The significance of the new drug which is dubbed "Stlesntre" (Selzentry) is that the only drug in the world markets, which he can close the one most important entry points used by HIV to destroy the white blood cells responsible for immunity of the body, known as the "agent receiver CCR5".
Pfizer Inc. said U.S. manufacturer of the drug that the drug will be available in the market from next month, and confirmed that its price will be equal to the price of similar drugs.
He said experts are neutral, that feature the new drug is its ability to respond to the disease in advanced stages make it the first of a new generation of treatment, as research has shown that people with defects in the work of CCR5 are better protected against AIDS, and its spread within their bodies in case of infection is very slow .
But experts have suggested that the only obstacle to the production of a drug intended to treat "factor reception CCR5," was the high proportion of dangerous side effects, and the possibility of exposure to significant damage to the heart or liver, as well as increase the risk of infections and the spread of cancer.
However, the Food and Drug Administration has not gone unnoticed by those caveats, is viewed as consent to "Stlesntre" comes in the context of the granting of "new option" for patients with difficult cases, calling the manufacturer to carry out more developmental research.
And Drug Affairs Officer suspended in the administration, Dr. Debra Brinkerant "draw benefit from the drug outweigh harms, and this does not mean that the risks do not exist ... the drug is designated for the process of his body has become resistant to various types of AIDS medicines, which is not for people with recently."
The researchers say that HIV known as HIV, which currently comes in fourth place in the list of diseases, the most deadly after heart disease, stroke and respiratory diseases - is about to occupy the third place, where he is the disease on approximately 2.8 million people annually.
Researchers predict that the number of deaths with the disease over the next twenty-five to about 120 million people.
ليست هناك تعليقات:
إرسال تعليق